Merck aims to hike revenues in China to 1 billion euro by 2018
FRANKFURT (Reuters) - Merck (MRCG.DE) will start offering non-prescription drugs in China as part of a push to double revenues in the region to 1 billion euros ($1.3 billion) by 2018, Chief Executive Karl-Ludwig Kley told German weekly Wirtschaftswoche.
Merck will focus on treatments related to diabetes, thyroid issues and heart problems, and supply medication made at a new factory in Nantong which is due to start production in 2017, Wirtschaftswoche said.
($1 = 0.7447 Euros)
(Reporting by Edward Taylor; Editing by Ruth Pitchford)